

1 **Comparison of antigen- and RT-PCR-based testing strategies for detection of Sars-Cov-2** 2 **in two high-exposure settings**

3 Jay Love¹, Megan T. Wimmer², Damon J.A. Toth¹, Arthi Chandran², Dilip Makhija², Charles K.
4 Cooper², Matthew H. Samore¹, Lindsay T. Keegan¹

5 Affiliations: ¹University of Utah; ²Becton, Dickinson, and Company

6 **Abstract**

7 Surveillance testing for infectious disease is an important tool to combat disease transmission at
8 the population level. During the SARS-CoV-2 pandemic, RT-PCR tests have been considered
9 the gold standard due to their high sensitivity and specificity. However, RT-PCR tests for SARS-
10 CoV-2 have been shown to return positive results when administered to individuals who are past
11 the infectious stage of the disease. Meanwhile, antigen-based tests are often treated as a less
12 accurate substitute for RT-PCR, however, new evidence suggests they may better reflect
13 infectiousness. Consequently, the two test types may each be most optimally deployed in
14 different settings. Here, we present an epidemiological model with surveillance testing and
15 coordinated isolation in two congregate living settings (a nursing home and a university
16 dormitory system) that considers test metrics with respect to viral culture, a proxy for
17 infectiousness. Simulations show that antigen-based surveillance testing coupled with isolation
18 greatly reduces disease burden and carries a lower economic cost than RT-PCR-based strategies.
19 Antigen and RT-PCR tests perform different functions toward the goal of reducing infectious
20 disease burden and should be used accordingly.

21 **Introduction**

22 Since its emergence in late 2019, SARS-CoV-2, the virus responsible for COVID-19, has spread
23 rapidly, causing significant global morbidity and mortality. Although early outbreaks were
24 concentrated in China and Italy, the United States (US) was the global epicenter for most of
25 2020, accounting for approximately one fourth of all cases globally by March 2021 (Dong, Du,
26 & Gardner, 2020). Despite the approval of multiple SARS-CoV-2 vaccines, production,
27 distribution, and uptake hurdles combined with the emergence of novel viral variants indicates
28 that achieving herd immunity remains a distant prospect (Moore & Offit, 2021; Sallam, 2021).
29 Therefore, comprehensive testing, contact tracing, and infectious case isolation remain important
30 interventions to continue slowing the spread of SARS-CoV-2 and maintaining health system
31 integrity (Love et al., 2021).

32 As testing availability has increased, epidemiological questions have arisen regarding the optimal
33 deployment of different test strategies. Diagnostic tests for SARS-CoV-2, none of which
34 perfectly reflect viral carriage (Woloshin et al. 2020), fall into two broad categories: antigen tests
35 and real-time reverse transcription polymerase chain reaction (RT-PCR) tests. While both tests
36 diagnose active SARS-CoV-2 infection, antigen tests detect the presence of a specific viral
37 antigen and are capable of returning results within 15 minutes, while RT-PCR amplify genomic
38 sequences and therefore require longer turn-around times (CDC 2021a). Substantial attention has
39 been paid to the lower sensitivity of antigen testing compared with that of RT-PCR testing

40 (Schohy et al., 2020). Early studies on SARS-CoV-2 antigen testing sensitivity reported relatively
41 low sensitivity with respect to RT-PCR, leading some public health officials to place lower
42 confidence in antigen testing than RT-PCR testing in ending the COVID-19 pandemic. However,
43 it has been suggested that when comparing antigen- and RT-PCR tests to viral culture, a proxy
44 for transmissibility, one rapid antigen test (Becton Dickinson Veritor) had a negative percent
45 agreement of 96.4% (95% CI: 82.3, 99.4) and a positive percent agreement of 90.0% (CI: 76.3,
46 97.6), while positive percent agreement for the RT-PCR assay was 73.7% (CI: 60.8, 85.3)
47 (Pekosz et al., 2021). These studies suggest that antigen tests may perform better than RT-PCR
48 tests at detecting actively infectious infections, since RT-PCR tests may detect low levels of viral
49 nucleic acid that may not indicate current infectiousness (CDC 2020a). Consequently, the two
50 different test types may have different optimal strategies for deployment. The more rapid antigen
51 tests may be more optimally deployed when a delay in test results will delay the isolation of an
52 infectious infection (e.g., Larremore et al., 2021), while RT-PCR tests may be more optimally
53 deployed when diagnosing every infection or disease case is critical (e.g., Wang et al., 2020).

54 Recent studies have demonstrated that regardless of test sensitivity, widespread, high-frequency
55 testing is sufficient to significantly reduce the burden of COVID-19 (Larremore et al., 2021;
56 Mina, Parker, & Larremore, 2020; Paltiel, Zheng, & Walensky, 2020). While this finding
57 highlights the importance of surveillance testing, it does not provide an explicit decision-support
58 framework for clinical and public health decisionmakers for testing strategies in congregate
59 settings. Building on such past work, we investigate the population-level epidemiological effects
60 of employing different COVID-19 surveillance testing strategies, including RT-PCR, antigen,
61 and two reflex testing strategies, in two non-acute care congregate living settings that bookend
62 the risk spectrum: a nursing home and a university residence hall system.

63

64 **Methods**

65 **Epidemiological model**


66 The epidemiological model is comprised of a dynamical model of SARS-CoV-2 with a layered
67 statistical model of hospitalizations, ICU hospitalizations, and deaths.

68 ***Transmission dynamics model***

69 We developed a compartmental model of SARS-CoV-2 transmission dynamics with surveillance
70 testing by modifying a *Susceptible-Exposed-Infectious-Removed* (SEIR) model and including
71 individual-based accounting of infectious state (Figure 1). There are two simultaneous processes
72 in the model: the disease process and the testing process. In the disease process (Figure 1),
73 individuals start as fully susceptible (S) and become exposed (E) according to a density-
74 dependent probability of exposure. This probability is defined as the product of a rate β and the
75 infectious proportion of the population, accounting for quarantine and isolation, as described
76 below (see Equation S1). The value of β is derived from the product of R_0 , which we assume to
77 be uniformly distributed between 1.2 and 1.5 (Zhang, Keegan, Qiu, & Samore, 2020), and the
78 recovery rate, γ , which we assume to be uniformly distributed between 1/2.6 and 1/6 per day

79 (Lin et al., 2020). Exposed individuals have had a successful exposure event but are not yet
 80 infectious; they become infectious (I) at a rate σ and are then able to infect others. We assume σ
 81 is 1/3 (Peirlinck, Linka, Sahli Costabal, & Kuhl, 2020). Infected individuals are
 82 removed/recover (R) at a rate γ . The removed/recovered compartment indicates individuals who
 83 are no longer infectious, which includes both recovered and dead individuals; we use the classic
 84 epidemiologic definition of this term, and do not use it to refer to a clinical recovery. We seed
 85 our simulations based on a prevalence of 1.8% in the residence hall setting and 3.6% in the
 86 nursing home setting.

87 In the testing process (Figure 1), we assume a fixed proportion of the population, τ , is tested each
 88 day (surveillance testing). The assumptions and parameter values for our baseline simulation
 89 settings are as follow (Table S1). We assume that susceptible individuals who test positive (T_S ;
 90 false positive) do so at a rate of $\phi_a = 0.0001$ to account for imperfect test specificity. For tested
 91 exposed (T_E) and tested recovered (T_R) individuals, we use the negative percent agreement of
 92 each test compared to culture reported in published analyses for RT-PCR ($\phi_p = 95.5\%$) and for
 93 antigen tests ($\phi_p = 98.7\%$) (Pekosz et al., 2021). For tested infectious individuals (T_I), we use the
 94 antigen test positive percent agreement $\phi_e = 96.4\%$ and RT-PCR positive percent agreement
 95 $\phi_e = 100\%$ reported in the same analysis (Pekosz et al., 2021). We assume that individuals who
 96 test positive are isolated (Q) and are returned from isolation after an average of 14 days ($\omega =$
 97 0.07 in figure 1, though return from isolation is determined as $1/\omega$ days after the start of
 98 isolation; see below); we also explore a shorter 10-day isolation (see supplement). We assume
 99 that patients will reduce their mixing while awaiting test results and therefore are both less
 100 susceptible and less infectious. As a baseline assumption, we use a 50% reduction in mixing due
 101 to this partial quarantine (q). We also explore two additional possible reductions of 25% and



102 75% (Figures S6, S7). Other than this partial quarantine, tested individuals move through the
 103 disease course as normal. Test results for antigen testing are returned on the same day as test
 104 administration ($\theta = 1$), while results are returned in 48 hours for RT-PCR ($\theta = 1/3$), an
 105 approximation for the US average time for RT-PCR test result turnaround (as in Larremore et al.,

106 2021). We explore two additional possible RT-PCR test turnaround times of 1 and 4 days in the
107 supplement.

108 **Figure 1. Schematic of the COVID-19 epidemiologic model.** Individuals in the population
109 start as susceptible (S) and become exposed (E) at a rate β . Exposed individuals become
110 infectious (I) at a rate σ , and recover (R) at a rate γ . Simultaneously, surveillance testing occurs
111 at a rate proportional to the population make up, and individuals awaiting test results are in a
112 “leaky” quarantine. Tested susceptibles (T_S) can become exposed (T_E), then infectious (T_I), and
113 can infect susceptibles (both S and T_S). Since tested infectious individuals (T_I) are quarantining,
114 their infectiousness is reduced by a factor q . Likewise, since tested susceptibles (T_S), are also
115 quarantining, their susceptibility is reduced by a factor q . Individuals who test positive are
116 isolated (Q). We assume isolation is perfect, and thus individuals can only progress through their
117 disease process ($Q_E \rightarrow Q_I \rightarrow Q_R$); susceptibles who are isolated cannot become infected and
118 infected individuals who are isolated cannot cause infections. After the isolation period is over
119 (14 days in the standard condition), individuals are returned to the general population, retaining
120 their current disease state. Antigen and RT-PCR tests have a specified positive (ϕ_e) and negative
121 percent agreement (ϕ_p) with viral culture (see text). ϕ_a is 0.0001, representing imperfect test
122 specificity. Note that we use positive percent agreement for tests of infectious individuals (I) and
123 negative percent agreement for both exposed (E) and recovered (R) individuals, as it has been
124 shown that RT-PCR may detect infection among individuals who are no longer infectious
125 (Kohmer et al., 2021). Here, the color and line-type of the arrows indicate whether or not the test
126 was “correct” or “incorrect” with respect to infectiousness, with dotted lines indicating incorrect
127 test results (i.e., false negative or false positive), red lines indicating a positive test, blue lines
128 indicating a negative test, black lines indicating that no test result was returned.

129 We assume isolation resulting from a positive test result is perfect, and thus individuals can only
130 progress through their disease process ($Q_E \rightarrow Q_I \rightarrow Q_R$); susceptibles who are isolated cannot
131 become infected and infected individuals who are isolated cannot cause infections. After the
132 isolation period is over (14 days in the standard condition), individuals are returned to the
133 general population, retaining their current disease state.

134 ***Test Settings***

135 We selected two settings to bookend the risk spectrum for communal living scenarios: a nursing
136 home, where disease outcomes are more severe, and a university residence hall system, where
137 disease outcomes are less severe. In the nursing home setting, the population was 101,
138 hospitalization rate was 25% of infections, ICU admission rate was 35.3% of hospitalizations,
139 and the fatality rate was 5.4% of total infections. In the residence hall system setting, the
140 population was 3150, hospitalization rate was 3.9% of infections, ICU admission rate was 23.8%
141 of hospitalizations, and the fatality rate was 0.01% of total infections (values reflect estimates
142 from CDC pandemic planning scenarios and expert guidance; CDC 2020b).

143 ***Testing strategies***

144 We explore five testing strategies for each of these two settings and assumed asymptomatic
145 screening of 1%, 2%, 5%, and 10% of the population each day. In each setting and for each

146 testing strategy, we ran the simulation for a duration of 183 days. The five testing strategies are
147 as follows:

- 148 1. Test once with RT-PCR test (“stand-alone PCR”)
- 149 2. Test once with antigen test (“stand-alone antigen”)
- 150 3. Test once with antigen test, then retest all negative results with antigen test two days later
151 (“reflex to antigen”)
- 152 4. Test once with antigen test, then retest all symptomatic negative results with RT-PCR test
153 (“reflex symptomatic to PCR”)
- 154 5. No surveillance testing (“no testing”)

155 Testing strategy 4 relies on symptom presentation to flag symptomatic individuals with negative
156 antigen tests for retesting. We assume that 60% of all infections are symptomatic (CDC 2020b).
157 To account for the potential influence of other circulating respiratory infections, we also assume
158 a background rate of 2% of the population expressing symptoms of influenza-like illness that are
159 unrelated to but could be confused with infection with SARS-CoV-2 (Tokarz et al., 2019; CDC
160 2021b). Individuals expressing influenza-like illness symptoms are randomly drawn from the
161 population each day with a 2% probability. Individuals expressing symptoms of COVID-19 or
162 influenza-like illness are flagged for retesting with RT-PCR in this strategy. Those individuals
163 flagged for retesting are quarantined in the same way as individuals awaiting test results.

164 To determine the relative impact of different testing strategies on the disease course, we compare
165 a suite of metrics between the four testing strategies and against the output of the model in the
166 absence of testing. The metrics reported are number of infections averted, hospitalizations
167 averted, deaths averted, and the per test reduction in infections.

168 Since using testing metrics with respect to viral culture as a proxy for infectiousness is a novel
169 approach to modeling infectious disease surveillance testing strategy effectiveness, we also
170 conducted simulations using antigen test sensitivity and specificity with respect to RT-PCR test
171 results. RT-PCR is capable of detecting levels of viral RNA that do not indicate infectiousness
172 (i.e., “recovered” in our model) (Mina et al., 2020). While our main simulations use test positive
173 percent agreement to determine test results exclusively for infectious individuals, in these
174 alternate simulations, we use test sensitivity to determine test results for both infectious and
175 recovered individuals less than 54 days after recovery, approximating the median duration of
176 RT-PCR detectable viral shedding in one analysis of 36 patients (Li, Wang, & Lv, 2020). We use
177 test specificity to determine test results for susceptible and exposed classes and recovered
178 individuals more than 54 days after recovery in these alternate simulations. Test sensitivity and
179 specificity are positive percent agreement with RT-PCR results, considered the testing standard.
180 Therefore, RT-PCR sensitivity and specificity are 100%, whereas antigen test sensitivity was
181 84.7% and specificity was 99.5%, following published results (Young et al. 2021).

182 We constructed the model in the R statistical environment (R Core Team, 2017). The discrete-
183 time model includes flows between states that are determined by rates at the population level and
184 by functions at the individual-level. The time step is one day. The probability of exposure is
185 frequency dependent and varies at each time step and across individuals. It is the product of the
186 infected and unquarantined proportion of the population at each time step and β plus the product

187 of the infected and quarantined proportion, the mixing rate reduction due to quarantine (q),
188 and β . β is determined by the product of random draws from uniformly-distributed values of $R0$
189 and γ . The probability of becoming infectious is determined by the rate σ . Recovery, however, is
190 modeled not with a population-level rate (γ), but with an individual-based approach using a fixed
191 duration of infectiousness; for each infection, a recovery day is designated that is $1/\gamma$ time steps
192 from the day of infection. Similarly, tests are returned by defining a day of test return for each
193 test that is $1/\theta$ time steps from the day of testing, and return from isolation is determined by
194 defining an end day to the isolation period as $1/\omega$ days after isolation begins.

195 We conducted 10,000 stochastic simulations for each testing strategy in each setting.

196 ***Economic Model***

197 To improve the decision support aspect of our model, we layered a cost effectiveness analysis on
198 top of the epidemiological model to estimate the costs of each testing strategy relative to the
199 relevant outcomes. We used parameter values estimated from literature sources and expert input
200 (Table S2). All costs were expressed in 2021 US dollars and are from the perspective of the
201 congregate setting decision makers. We estimated total testing and outcome costs per strategy
202 and calculated Cost per Incremental Infection Avoided and Unnecessary Quarantine Costs. We
203 also calculated Incremental Cost Effectiveness Ratios (ICER) to compare the four testing
204 strategies with the no testing strategy using the following standard calculation: ICER =

$$205 \frac{\Delta \text{costs}}{\Delta \text{outcome}}.$$

206 ***Testing Strategy Costs***

207 We considered the direct cost of testing to be the product of the number of tests per day, price
208 per test per day, personal protective equipment (PPE) costs per day, and labor costs per day. For
209 each type of test, the total cost is the sum of these daily costs multiplied by the duration of the
210 simulation. We assume that RT-PCR is sent to an external laboratory and therefore has no direct
211 capital costs to the decision maker, and we assume PPE is the same for either type of testing. The
212 no test strategy by definition has no direct testing costs.

213 ***Outcomes Cost Model***

214 We then consider the direct costs to the decision makers who purchase and conduct testing in
215 each of our two settings: universities and nursing homes. For nursing homes, staff absenteeism
216 due to quarantine incurs costs measured in labor productivity loss, a cost limited to staff, and a
217 conservative proxy for true costs which could include temporary staff and other costs. Positive
218 test results in either residents or staff incur labor costs for the administrative burden of reporting
219 positives and initiating cleaning protocols. For positive residents, additional PPE and labor costs
220 are incurred due to assumed need for isolation and additional staff care for those residents. Total
221 outcomes cost is therefore calculated as:

$$222 O_n \text{costs} = \left(\frac{\text{labor cost}}{I_{Res}} + \frac{\text{cleaning/precautions}}{I} + \frac{\text{PPE cost}}{Q_{Res}} + \frac{\text{reporting cost}}{I} \right) \cdot I$$

222

224 where

$$\begin{aligned} 225 \quad PPE \text{ cost} &= \left(glove \text{ cost} \cdot \frac{gloves}{test} \cdot tests \right) + \left(\frac{masks}{day} \cdot mask \text{ cost} \right) \\ 226 \quad &+ \left(face \ shield \ cost \cdot \frac{face \ shields}{day} \right) + \left(\frac{gowns}{day} \cdot gown \ cost \right) \end{aligned}$$

227 and where labor cost is the product of the hourly wage and the number of hours worked for each
228 healthcare worker type.

229 For university residence halls, the cost per infection ($O_n \text{ costs}$) was provided based on expert
230 input.

231 See Table S2 for cost parameter values and references.

232 Results

233 Compared to simulations without testing, all testing strategies reduced the peak and total
234 infections in simulated epidemics (Figure 1). Greater reduction in infections was achieved with
235 higher rates of daily screening. The relative differences between testing strategies' performance
236 in reducing infections were largely maintained across both nursing home and dormitory settings.




Figure 2. Epidemic curves showing infections over time in the nursing home (left) and residence hall (right) group living settings and at 2% and 10% daily surveillance testing. Higher levels of testing reduce infections. Different test strategies perform similarly. Line color indicates testing strategy.

237 In the nursing home setting, no statistically significant differences were found in % infections
238 averted across testing strategies at low levels of surveillance testing (1%, 2%). At high levels of

239 surveillance testing (5%, 10%), the reflex to antigen strategy (34% and 53% averted)
 240 outperformed standalone PCR (26% and 44% averted), which outperformed standalone antigen
 241 (20% and 35% averted) (Figures 2,3). The reflex symptomatic negatives to PCR strategy did not
 242 statistically significantly improve performance versus standalone antigen in any case (Figure 2).

243 These same broad trends were also observed in the university residence hall setting. For
 244 university dormitories under screening rates of 1%, the reflex to antigen strategy averted the
 245 highest percentage of infections (~6%), followed by standalone PCR (~5%), then standalone
 246 antigen (~3%). Standalone antigen testing and reflexing symptomatic to PCR strategies were
 247 again statistically equivalent in infection reduction (~3%) (Figure 2). At higher daily screening
 248 rates, this overall pattern was largely conserved, yet exaggerated. For 5% and 10% daily testing,
 249 overall reduction of infection rates increased to 16-32%, and 34-64%, respectively (Figure 2).

250 Since hospitalizations and deaths are calculated as proportions of infections, hospitalizations
 251 averted and deaths averted follow patterns similar to that found in infections averted (Figure S1).
 252 Very few deaths occurred in the residence hall setting.

253 On a per-test basis, different testing strategies resulted in similar percent infections averted
 254 (Figure S8). At higher surveillance levels (i.e., 5% and 10% daily surveillance) and with larger
 255 populations (i.e., in the residence hall setting), standalone PCR testing showed a notably higher
 256 mean per-test percent infection averted (Figure S8).




Figure 3. Percent infections averted for different testing strategies at different daily surveillance testing percentages. Red = 10%, green = 5%, blue = 2%, black = 1% daily surveillance testing. Filled circles show means, whiskers show 95% CI. Text labels indicate values of upper and lower 95% confidence interval bounds.

257 Overall, surveillance testing reduces the disease burden in populations, and the effect of testing
 258 on measures of disease burden was greatest at the highest rates of testing. We found similar
 259 patterns in simulations that used different parameter values for days to PCR test return,
 260 quarantine mixing reduction, and days of isolation (See Figures S2-S7).

261 When evaluating antigen testing by modeling test sensitivity and specificity with respect to PCR,
262 we find that the performance difference between standalone antigen and PCR testing is greater
263 than when these test features are modeled with respect to viral culture (Figure S2). For example,
264 the difference between standalone PCR and antigen testing strategies in mean % infections
265 averted in the residence hall setting at 10% daily surveillance testing was roughly 20% when
266 evaluating test performance with respect to PCR (Figure S2b) but only roughly 15% when
267 evaluating test performance with respect to viral culture (Figure 3).

268 The economic analysis revealed that antigen-based strategies carried an overall lower economic
269 cost than did RT-PCR-based strategies. At 2% and 10% screening rates, respectively, over the 6-
270 month period in nursing homes, the testing strategy of standalone antigen testing was least
271 expensive in terms of overall testing costs overall testing costs (\$25,037 and \$48,445), total costs
272 (\$38,250 and \$77,460) and testing cost per infection (\$544 and \$1,514) (Table 1). For university
273 dormitories, a similar pattern was evident (testing costs \$486,074 and \$952,940, total costs
274 \$798,147 and \$1,445,972, testing cost per infection \$419 and \$840, at 5% and 10% screening per
275 6 months, respectively) (Table 1). The overall testing and total costs are higher for the university
276 residence hall setting, reflecting the larger population and higher number of tests needed. In the
277 residence hall setting, the cost per person is lower than that of the nursing home setting,
278 demonstrating efficiencies of scale.

279 Due to the low number of occurring retests, the reflex symptomatic to PCR strategy had costs
280 very similar to standalone antigen testing (Table 1). Importantly, stand-alone PCR resulted in the
281 highest costs of all of the testing strategies.

282 Strategies that resulted in longer test result wait time increased unnecessary quarantine costs,
283 with stand-alone PCR resulting in the highest of these across settings at all screening rates,
284 ranging from 1.61-2.34 times as costly as the testing strategy with the least unnecessary
285 quarantine costs (Table 1). ICERs were calculated for all testing strategies. Antigen-based
286 strategies averaged lower ICERs than PCR-based strategies (Table 1).

287

288 **Discussion**

289 Our model demonstrates that surveillance testing paired with quarantine and isolation is likely to
290 reduce disease burden in congregate living settings during the COVID-19 pandemic. Higher
291 rates of screening result in the strongest reduction in infections and are associated with greater
292 distinction between the performance of different testing strategies. At low screening rates, testing
293 strategies performed similarly to each other. Despite differences in population size and
294 underlying risk, both residence hall and nursing home settings showed reduced disease burden
295 with increased surveillance testing.

296 Notably, the degree to which the standalone PCR testing strategy prevents infections is highly
297 contingent on the effectiveness of quarantine during the test-result waiting period. At low
298 waiting-period quarantine effectiveness, standalone PCR testing outperforms standalone antigen
299 testing to a lesser degree than at higher waiting-period quarantine effectiveness (Figures 2, 3, S6,

300 S7). If individuals awaiting surveillance test results do not undergo quarantine, as may occur in
301 some settings, the difference between these two testing strategies is likely to be less pronounced.

302 While the reflex to antigen strategy was the most effective at reducing infections, standalone
303 antigen testing was the least expensive and most cost-effective testing strategy in both settings at
304 all screening rates, due primarily to differences in test prices. Standalone PCR testing performed
305 well, but it was outperformed by the reflex to antigen strategy, both in terms of economic cost
306 and of reducing disease burden.

307 During the COVID-19 pandemic, RT-PCR testing has been established as the standard by which
308 to measure other tests. Our modeling analysis demonstrates that using viral culture, which may
309 better reflect viral transmissibility (Pekosz et al., 2021), as the test standard dramatically alters
310 the relative performance of different surveillance testing strategies. Under this paradigm,
311 antigen-based surveillance testing strategies coupled with infectious case isolation are shown to
312 strongly reduce disease burden at a level close to RT-PCR-based strategies, but at a much lower
313 economic cost (Figures 2,3), somewhat in contrast to model results under a more typical RT-
314 PCR test-standard paradigm (Figure S2). This lower cost has the potential to make additional
315 resources available for other management, containment, or recovery efforts, and therefore has the
316 potential to substantially reduce disease burden during the COVID-19 pandemic or others in the
317 future. Understanding test results with the priority endpoint in mind (e.g., the test's ability to
318 identify currently infectious infections during surveillance testing programs) should be of
319 primary importance, and our modelling study should prompt further research on the relationship
320 between viral culture, diagnostic test results, and transmissibility for SARS-CoV-2 and other
321 infectious diseases.

322 The cost perspective of this model may be of use to public health decision makers in determining
323 whether or not to invest in surveillance testing, but it does not account for the broader costs to
324 society and the healthcare system. An expanded or alternative perspective to this model that
325 could estimate the indirect societal costs of infection, disease, and quarantine would likely yield
326 more robust cost-effectiveness values and ICERs compared to those we find here.

327 Our results support the work of other studies that demonstrate that frequency of testing can
328 overcome differences in sensitivity (e.g., Larremore et al. 2021). In an important addition, we
329 provide a pragmatic example of an affordable and effective strategy that is implementable in two
330 group-living settings. As vaccine uptake remains low in many group living settings (e.g.,
331 Cavanaugh et al. 2021), and as a greater understanding of the potential for immune escape
332 mutants is developed (Garcia-Beltran et al., 2021), surveillance testing strategies that use antigen
333 tests can be considered as highly effective, cost-reducing alternatives to PCR testing strategies.

334 **References**

335 Cavanaugh, A. M., Fortier, S., Lewis, P., Arora, V., Johnson, M., George, K., Tobias, J., Lunn,
336 S., Miller, T., Thoroughman, D., & Spicer, K. B. (2021). COVID-19 Outbreak Associated
337 with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination
338 Program - Kentucky, March 2021. *MMWR. Morbidity and Mortality Weekly Report*, 70(17),
339 639–643. doi:10.15585/mmwr.mm7017e2

- 340 CDC (2021a). Overview of Testing for SARS-CoV-2 (COVID-19). March 17, 2021.
341 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html> (accessed March
342 17, 2021).
- 343 CDC (2021b) FLUVIEW: U.S. Influenza Surveillance System. October 6, 2020.
344 <https://www.cdc.gov/flu/weekly/overview.htm> (accessed June 1, 2021).
- 345 CDC (2020a) Interim Guidance for Antigen Testing for Sars-Cov-2.
346 <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html>
347 (accessed March 17, 2021).
- 348 CDC (2020b) COVID-19 Pandemic Planning Scenarios. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html> (accessed March 17th, 2021)
- 350 Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19
351 in real time. *The Lancet Infectious Diseases*, 20(5), 533–534.
352 [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
- 353 Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., ...
354 Balazs, A. B. (2021). Circulating SARS-CoV-2 variants escape neutralization by vaccine-
355 induced humoral immunity. *MedRxiv*, 2021.02.14.21251704.
356 <https://doi.org/10.1016/j.cell.2021.03.013>
- 357 Kohmer, N., Toptan, T., Pallas, C., Karaca, O., Pfeiffer, A., Westhaus, S., ... Rabenau, H. F.
358 (2021). The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests
359 and Their Correlation to Infectivity In Vitro. *Journal of Clinical Medicine*, 10(2), 328.
360 <https://doi.org/10.3390/jcm10020328>
- 361 Larremore, D. B., Wilder, B., Lester, E., Shehata, S., Burke, J. M., Hay, J. A., ... Parker, R.
362 (2021). Test sensitivity is secondary to frequency and turnaround time for COVID-19
363 screening. *Science Advances*, 7(1), 1–11. <https://doi.org/10.1126/sciadv.abd5393>
- 364 Li, N., Wang, X., & Lv, T. (2020). Prolonged SARS-CoV-2 RNA shedding: Not a rare
365 phenomenon. *Journal of Medical Virology*, 92(11), 2286–2287.
366 <https://doi.org/10.1002/jmv.25952>
- 367 Lin, Q., Zhao, S., Gao, D., Lou, Y., Yang, S., Musa, S. S., ... He, D. (2020). A conceptual model
368 for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual
369 reaction and governmental action. *International Journal of Infectious Diseases*, 93, 211–
370 216. <https://doi.org/10.1016/j.ijid.2020.02.058>
- 371 Love, J., Keegan, L. T., Angulo, F. J., McLaughlin, J., Shea, K. M., Swerdlow, D. L., ... Toth,
372 D. J. (2021). Continued need for non-pharmaceutical interventions after COVID-19
373 vaccination in long-term- care facilities. *MedRxiv*.
374 <https://doi.org/10.1101/2021.01.06.21249339>
- 375 Mina, M. J., Parker, R., & Larremore, D. B. (2020). Rethinking Covid-19 Test Sensitivity - A
376 Strategy for Containment. *New England Journal of Medicine*, 383(22).
377 <https://doi.org/10.1056/NEJMp2025631>
- 378 Moore, J. P., & Offit, P. A. (2021). SARS-CoV-2 Vaccines and the Growing Threat of Viral
379 Variants. *JAMA - Journal of the American Medical Association*, 4399(August 2020), 2020–
380 2021. <https://doi.org/10.1001/jama.2021.1114>
- 381 Paltiel, A. D., Zheng, A., & Walensky, R. P. (2020). Assessment of SARS-CoV-2 Screening

- 382 Strategies to Permit the Safe Reopening of College Campuses in the United States. *JAMA*
383 *Network Open*, 3(7), e2016818. <https://doi.org/10.1001/jamanetworkopen.2020.16818>
- 384 Peirlinck, M., Linka, K., Sahli Costabal, F., & Kuhl, E. (2020). Outbreak dynamics of COVID-
385 19 in China and the United States. *Biomechanics and Modeling in Mechanobiology*, 19(6),
386 2179–2193. <https://doi.org/10.1007/s10237-020-01332-5>
- 387 Pekosz, A., Parvu, V., Li, M., Andrews, J. C., Manabe, Y. C., Kodsí, S., ... Cooper, C. K.
388 (2021). Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates
389 With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. *Clinical Infectious*
390 *Diseases*, 21205(Xx), 1–6. <https://doi.org/10.1093/cid/ciaa1706>
- 391 R Core Team. (2017). R: A language and environment for statistical computing. Vienna, Austria:
392 R Foundation for Statistical Computing.
- 393 Sallam, M. (2021). COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of
394 Vaccine Acceptance Rates. *Vaccines*, 9(2), 160.
- 395 Scohy, A., Anantharajah, A., Bodéus, M., Kabamba-Mukadi, B., Verroken, A., & Rodriguez-
396 Villalobos, H. (2020). Low performance of rapid antigen detection test as frontline testing
397 for COVID-19 diagnosis. *Journal of Clinical Virology*, 129(May), 104455.
398 <https://doi.org/10.1016/j.jcv.2020.104455>
- 399 Tokars, J. I., Olsen, S. J., & Reed, C. (2018). Seasonal Incidence of Symptomatic Influenza in
400 the United States. *Clinical Infectious Diseases*, 66(10), 1511–1518.
401 <https://doi.org/10.1093/cid/cix1060>
- 402 Wang, Y., Kang, H., Liu, X., & Tong, Z. (2020). Combination of RT-qPCR testing and clinical
403 features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak.
404 *Journal of Medical Virology*, 92(6), 538–539. <https://doi.org/10.1002/jmv.25721>
- 405 Woloshin, S., Patel, N., & Kesselheim, A. S. (2020). False Negative Tests for SARS-CoV-2
406 Infection — Challenges and Implications. *New England Journal of Medicine*, 383(e83).
407 doi:10.1056/NEJMp2015897
- 408 Young, S., Taylor, S. N., Cammarata, C. L., Roger-Dalbert, C., Montano, A., Griego-Fullbright,
409 C., Burgard, C., Fernandez, C., Eckert, K., Andrews, J. C., Ren, H., Allen, J., Ackerman, R.,
410 Gary, D., & Cooper, C. K. (2021). Clinical evaluation of BD Veritor SARS-CoV-2 point-
411 of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS
412 antigen point-of-care test. *Journal of Clinical Microbiology*, 59(1), 02338–20.
413 <https://doi.org/10.1128/JCM.02338-20>
- 414 Zhang, Y., Keegan, L. T., Qiu, Y., & Samore, M. H. (2020). The real time effective reproductive
415 number for COVID-19 in the United States. *MedRxiv*, 10–13.
416 <https://doi.org/10.1101/2020.05.08.20095703>
- 417
- 418
- 419
- 420

Surveillance %	Setting	Testing strategy	Testing cost per infection	Total testing cost	Total Costs	Per person testing cost	Cost per incremental infection avoided	
1%	NH	1	PCR	\$659.40	\$31,652.69	\$43,324.77	\$10.05	\$12,840.77
	NH	2	Antigen	\$459.99	\$22,125.35	\$29,174.74	\$7.02	\$9,007.33
	NH	3	retest all negatives with antigen	\$539.16	\$24,959.52	\$35,762.94	\$7.92	\$6,012.60
	NH	4	retest negative symptomatic PCR	\$471.29	\$22,167.77	\$29,708.94	\$7.04	\$6,707.82
	NH	5	None					
	Dorms	1	PCR	\$298.35	\$485,242.81	\$609,273.18	\$154.05	\$4,043.76
	Dorms	2	Antigen	\$68.10	\$112,601.12	\$184,479.47	\$35.75	\$1,485.94
	Dorms	3	retest all negatives with antigen	\$126.32	\$202,452.15	\$348,270.93	\$64.27	\$1,714.37
	Dorms	4	retest negative symptomatic PCR	\$67.97	\$112,599.40	\$185,112.30	\$35.75	\$1,521.70
	Dorms	5	None					
2%	NH	1	PCR	\$1,063.56	\$46,654.07	\$67,441.43	\$14.81	\$7,461.16
	NH	2	antigen	\$544.68	\$25,037.09	\$38,250.02	\$7.95	\$5,331.76
	NH	3	retest all negatives with antigen	\$703.20	\$30,636.99	\$49,059.50	\$9.73	\$4,538.34
	NH	4	retest negative symptomatic PCR	\$551.15	\$25,109.82	\$38,597.40	\$7.97	\$5,058.64
	NH	5	None					
	Dorms	1	PCR	\$622.28	\$953,359.76	\$1,182,796.20	\$302.65	\$3,926.41
	Dorms	2	antigen	\$128.87	\$205,871.92	\$344,489.52	\$65.36	\$1,432.23
	Dorms	3	retest all negatives with antigen	\$257.34	\$384,030.53	\$652,701.97	\$121.91	\$1,667.43
	Dorms	4	retest negative symptomatic PCR	\$128.84	\$206,013.34	\$345,351.85	\$65.40	\$1,440.51
	Dorms	5	None					
5%	NH	1	PCR	\$3,066.44	\$91,330.75	\$129,235.64	\$913.31	\$6,569.19
	NH	2	antigen	\$1,063.42	\$33,839.19	\$59,210.23	\$338.39	\$3,357.35
	NH	3	retest all negatives with antigen	\$1,987.85	\$47,376.39	\$76,359.32	\$473.76	\$2,979.99
	NH	4	retest negative symptomatic PCR	\$1,030.46	\$33,973.28	\$60,181.84	\$339.73	\$3,650.04
	NH	5	none					

	Dorms	1	PCR	\$2,263.99	\$2,359,441.85	\$2,808,400.54	\$749.03	\$4,205.48
	Dorms	2	antigen	\$418.97	\$486,074.53	\$798,147.93	\$154.31	\$1,451.72
	Dorms	3	retest all negatives with antigen	\$1,088.13	\$919,568.27	\$1,425,698.88	\$291.93	\$1,648.46
	Dorms	4	retest negative symptomatic PCR	\$419.71	\$486,327.46	\$797,692.80	\$154.39	\$1,447.13
	Dorms	5	none					
10%	NH	1	PCR	\$5,981.02	\$165,931.49	\$210,071.39	\$1,659.31	\$6,880.82
	NH	2	antigen	\$1,514.33	\$48,445.07	\$77,460.72	\$484.45	\$2,695.88
	NH	3	retest all negatives with antigen	\$3,199.94	\$74,309.03	\$102,585.67	\$743.09	\$2,777.84
	NH	4	retest negative symptomatic PCR	\$1,556.56	\$48,636.12	\$77,438.30	\$486.36	\$2,636.02
	NH	5	none					
	Dorms	1	PCR	\$5,427.84	\$4,700,756.49	\$5,260,632.24	\$1,492.30	\$4,680.53
	Dorms	2	antigen	\$839.73	\$952,940.34	\$1,445,972.64	\$302.52	\$1,484.75
	Dorms	3	retest all negatives with antigen	\$2,864.65	\$1,779,042.18	\$2,312,562.13	\$564.78	\$1,677.51
	Dorms	4	retest negative symptomatic PCR	\$842.05	\$953,376.96	\$1,444,826.84	\$302.66	\$1,480.44
	Dorms	5	none					

421

Table 1. Results of the economic cost analysis. In both settings and at all levels of surveillance testing, the antigen-based testing strategy was least expensive. The “retest all negatives with antigen” strategy, which averted the most infections (Figure 3), was less expensive than PCR-based testing. The “retest negative symptomatic with PCR” strategy was similar in costs to the antigen-based testing strategy.